Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
West Pharmaceutical Services, Inc. (WST)
NYSE:WST
RESEARCH TOOLSreports
Holding WST?
Track your performance easily
WST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$265.00 - $413.70
Previous CloseN/A
Volume102.64K
Average Volume (3M)491.09K
Market Cap
$24.42B
Enterprise Value$21.85B
Total Cash (Recent Filing)$203.00M
Total Debt (Recent Filing)$226.20M
Price to Earnings (P/E)50.0
Beta0.86
Next Earnings
Feb 13, 2025EPS Estimate
1.72Last Dividend Ex-Date
Nov 13, 2024Dividend Yield0.24%
Share Statistics
EPS (TTM)6.74
Shares Outstanding72,422,350
10 Day Avg. Volume469,961
30 Day Avg. Volume491,092
Standard Deviation0.09
R-Squared0.31
Alpha0.00623
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.49
Price to Cash Flow (P/CF)33.90
P/FCF Ratio61.40
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue7.60
Enterprise Value/Gross Profit19.35
Enterprise Value/Ebitda28.80
Forecast
1Y Price Target
$384.50Price Target Upside14.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
West Pharmaceutical Services News
PremiumCompany Announcements
West Pharmaceutical Expands Board with New DirectorBulls Say, Bears Say
Bulls Say
Growth OpportunitiesThere are significant growth opportunities for High Value Products driven by a shift to biologics, a stricter regulatory environment, and GLP-1s.
Market ExpansionWeight loss drugs may be used in cardiovascular disease and chronic kidney disease, potentially expanding the market size for West's packaging materials.
Stable DemandThe demand for packaging is growing, with global daily medicine dosage increasing, which West can leverage to increase sales.
Bears Say
Customer BehaviorCustomer destocking in HVP-heavy Biologics continues, albeit improving modestly.
Financial PerformanceHVP devices are a drag on margins in the near-to-medium term.
Market OpportunityImprovements in drug efficacy may decrease dosing frequency, which could negatively impact West's sales and profitability.
---
Ownership Overview
0.56% Insiders
30.67% Mutual Funds
0.52% Other Institutional Investors
40.90% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
WST FAQ
What was West Pharmaceutical Services, Inc.’s price range in the past 12 months?
West Pharmaceutical Services, Inc. lowest stock price was $265.00 and its highest was $413.70 in the past 12 months.
What is West Pharmaceutical Services, Inc.’s market cap?
West Pharmaceutical Services, Inc.’s market cap is $24.42B.
When is West Pharmaceutical Services, Inc.’s upcoming earnings report date?
West Pharmaceutical Services, Inc.’s upcoming earnings report date is Feb 13, 2025 which is in 26 days.
How were West Pharmaceutical Services, Inc.’s earnings last quarter?
West Pharmaceutical Services, Inc. released its earnings results on Oct 24, 2024. The company reported $1.85 earnings per share for the quarter, beating the consensus estimate of $1.501 by $0.349.
Is West Pharmaceutical Services, Inc. overvalued?
According to Wall Street analysts West Pharmaceutical Services, Inc.’s price is currently Undervalued.
Does West Pharmaceutical Services, Inc. pay dividends?
West Pharmaceutical Services, Inc. pays a Quarterly dividend of $0.809 which represents an annual dividend yield of 0.24%. See more information on West Pharmaceutical Services, Inc. dividends here
What is West Pharmaceutical Services, Inc.’s EPS estimate?
West Pharmaceutical Services, Inc.’s EPS estimate is 1.72.
How many shares outstanding does West Pharmaceutical Services, Inc. have?
West Pharmaceutical Services, Inc. has 72,422,350 shares outstanding.
What happened to West Pharmaceutical Services, Inc.’s price movement after its last earnings report?
West Pharmaceutical Services, Inc. reported an EPS of $1.85 in its last earnings report, beating expectations of $1.501. Following the earnings report the stock price went up 15.434%.
Which hedge fund is a major shareholder of West Pharmaceutical Services, Inc.?
Among the largest hedge funds holding West Pharmaceutical Services, Inc.’s share is Intermede Investment Partners Ltd. It holds West Pharmaceutical Services, Inc.’s shares valued at 75M.
---
West Pharmaceutical Services Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$384.50 (14.32% Upside)
$384.50 (14.32% Upside)
Blogger Sentiment
Bullish
WST Sentiment 71%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 89.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $218.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.69%
12-Months-Change
Fundamentals
Return on Equity
17.78%
Trailing 12-Months
Asset Growth
-2.12%
Trailing 12-Months
Company Description
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
---
WST Company Deck
---
WST Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed performance for West Pharmaceutical, with strong revenue performance and strategic positioning in high-growth areas like biologics and contract manufacturing. However, the company faces challenges with organic sales decline, margin reductions, and ongoing destocking issues. Despite these challenges, increased guidance for adjusted EPS and strategic investments in growth areas provide a positive outlook.Read More>---
WST Revenue Breakdown
81.27% Proprietary Products
18.73% Contract-Manufactured Products
0.00% Intersegment sales elimination
---
WST Stock 12 Month Forecast
Average Price Target
$384.50
▲(14.32% Upside)
Technical Analysis
Bio-Rad Laboratories
―
Agilent
―
Baxter International
―
Becton Dickinson
―
Steris
―
DENTSPLY SIRONA
―
Best Analysts Covering WST
1 Year
1 Year Success Rate
8/9 ratings generated profit
1 Year Average Return
+10.18%
assigned a buy rating 2 months ago
Copying David Windley's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +10.18% per trade.
---